82 related articles for article (PubMed ID: 22513516)
1. Efficacy and safety of 10% HES 130/0.4 versus 10% HES 200/0.5 for plasma volume expansion in cardiac surgery patients.
Ertmer C; Wulf H; Van Aken H; Friederich P; Mahl C; Bepperling F; Westphal M; Gogarten W
Minerva Med; 2012 Apr; 103(2):111-22. PubMed ID: 22513516
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyethyl starch 130/0.42/6:1 for perioperative plasma volume replacement in children: preliminary results of a European Prospective Multicenter Observational Postauthorization Safety Study (PASS).
Sümpelmann R; Kretz FJ; Gäbler R; Luntzer R; Baroncini S; Osterkorn D; Haeger MC; Osthaus WA
Paediatr Anaesth; 2008 Oct; 18(10):929-33. PubMed ID: 18647272
[TBL] [Abstract][Full Text] [Related]
3. Volume replacement therapy during major orthopedic surgery using Voluven (hydroxyethyl starch 130/0.4) or hetastarch.
Gandhi SD; Weiskopf RB; Jungheinrich C; Koorn R; Miller D; Shangraw RE; Prough DS; Baus D; Bepperling F; Warltier DC
Anesthesiology; 2007 Jun; 106(6):1120-7. PubMed ID: 17525586
[TBL] [Abstract][Full Text] [Related]
4. Effects of intravascular volume therapy using hydroxyethyl starch (130/0.4) on post-operative bleeding and transfusion requirements in children undergoing cardiac surgery: a randomized clinical trial.
Chong Sung K; Kum Suk P; Mi Ja Y; Kyoung Ok K
Acta Anaesthesiol Scand; 2006 Jan; 50(1):108-11. PubMed ID: 16451158
[TBL] [Abstract][Full Text] [Related]
5. Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary bypass.
Boldt J; Lehmann A; Römpert R; Haisch G; Isgro F
J Cardiothorac Vasc Anesth; 2000 Jun; 14(3):264-8. PubMed ID: 10890478
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of hydroxyethyl starch 6% 130/0.4 in a balanced electrolyte solution (Volulyte) during cardiac surgery.
Base EM; Standl T; Lassnigg A; Skhirtladze K; Jungheinrich C; Gayko D; Hiesmayr M
J Cardiothorac Vasc Anesth; 2011 Jun; 25(3):407-14. PubMed ID: 21345699
[TBL] [Abstract][Full Text] [Related]
7. A randomized prospective analysis of alteration of hemostatic function in patients receiving tranexamic acid and hydroxyethyl starch (130/0.4) undergoing off pump coronary artery bypass surgery.
Chakravarthy M; Muniraj G; Patil S; Suryaprakash S; Mitra S; Shivalingappa B
Ann Card Anaesth; 2012; 15(2):105-10. PubMed ID: 22508200
[TBL] [Abstract][Full Text] [Related]
8. Rapidly degradable hydroxyethyl starch solutions impair blood coagulation after cardiac surgery: a prospective randomized trial.
Schramko AA; Suojaranta-Ylinen RT; Kuitunen AH; Kukkonen SI; Niemi TT
Anesth Analg; 2009 Jan; 108(1):30-6. PubMed ID: 19095827
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyethyl starch 130/0.42/6:1 for perioperative plasma volume replacement in 1130 children: results of an European prospective multicenter observational postauthorization safety study (PASS).
Sümpelmann R; Kretz FJ; Luntzer R; de Leeuw TG; Mixa V; Gäbler R; Eich C; Hollmann MW; Osthaus WA
Paediatr Anaesth; 2012 Apr; 22(4):371-8. PubMed ID: 22211931
[TBL] [Abstract][Full Text] [Related]
10. [The maximum safe dosage of the low molecular weight hydroxyethyl starch, HESPANDAR (HES), estimated from HES induced changes in coagulation parameters and clinical bleeding].
Saito Y; Uchida K; Yamamoto H; Ichiishi N; Matsushita F
Masui; 1999 Mar; 48(3):238-43. PubMed ID: 10214006
[TBL] [Abstract][Full Text] [Related]
11. Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients.
Haisch G; Boldt J; Krebs C; Suttner S; Lehmann A; Isgro F
J Cardiothorac Vasc Anesth; 2001 Jun; 15(3):316-21. PubMed ID: 11426361
[TBL] [Abstract][Full Text] [Related]
12. Safety of HES 130/0.4 (Voluven(R)) in patients with preoperative renal dysfunction undergoing abdominal aortic surgery: a prospective, randomized, controlled, parallel-group multicentre trial.
Godet G; Lehot JJ; Janvier G; Steib A; De Castro V; Coriat P
Eur J Anaesthesiol; 2008 Dec; 25(12):986-94. PubMed ID: 18492315
[TBL] [Abstract][Full Text] [Related]
13. [Effect of a new 10% hydroxyethyl starch solution HES/270/0.5 on blood coagulation, blood loss and hemodynamics in comparison with 3.5% PPL].
Penner M; Fingerhut D; Tacke A
Infusionstherapie; 1990 Dec; 17(6):314-8. PubMed ID: 1709146
[TBL] [Abstract][Full Text] [Related]
14. Volume replacement with a balanced hydroxyethyl starch (HES) preparation in cardiac surgery patients.
Boldt J; Mayer J; Brosch C; Lehmann A; Mengistu A
J Cardiothorac Vasc Anesth; 2010 Jun; 24(3):399-407. PubMed ID: 20510247
[TBL] [Abstract][Full Text] [Related]
15. Changes in acid-base, electrolyte and hemoglobin concentrations during infusion of hydroxyethyl starch 130/0.42/6 : 1 in normal saline or in balanced electrolyte solution in children.
Sümpelmann R; Witt L; Brütt M; Osterkorn D; Koppert W; Osthaus WA
Paediatr Anaesth; 2010 Jan; 20(1):100-4. PubMed ID: 19968805
[TBL] [Abstract][Full Text] [Related]
16. The safety of modern hydroxyethyl starch in living donor liver transplantation: a comparison with human albumin.
Mukhtar A; Aboulfetouh F; Obayah G; Salah M; Emam M; Khater Y; Akram R; Hoballah A; Bahaa M; Elmeteini M; Hamza A
Anesth Analg; 2009 Sep; 109(3):924-30. PubMed ID: 19690268
[TBL] [Abstract][Full Text] [Related]
17. Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects.
de Jonge E; Levi M; Büller HR; Berends F; Kesecioglu J
Intensive Care Med; 2001 Nov; 27(11):1825-9. PubMed ID: 11810130
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for cardiopulmonary bypass priming: the effects on postoperative bleeding and volume expansion needs after elective CABG.
Vanhoonacker J; Ongenae M; Vanoverschelde H; Donadoni R
Acta Anaesthesiol Belg; 2009; 60(2):91-7. PubMed ID: 19594090
[TBL] [Abstract][Full Text] [Related]
19. [Changes in blood coagulation in treatment with hydroxyethyl starch].
Sefrin P; Rauch S; Zieglmeyer C
Anaesthesiol Reanim; 1998; 23(6):149-56. PubMed ID: 10036794
[TBL] [Abstract][Full Text] [Related]
20. Six percent hydroxyethyl starch 130/0.4 (Voluven®) versus 5% human serum albumin for volume replacement therapy during elective open-heart surgery in pediatric patients.
Van der Linden P; De Villé A; Hofer A; Heschl M; Gombotz H
Anesthesiology; 2013 Dec; 119(6):1296-309. PubMed ID: 23934169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
